(S)-methyl 2-((S)-2-((S)-2-((2R,3S)-3-((2S,4R,5R,6R)-4-((2S,4R,5S,6R)-4-((2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-7-((2S,4R,5R,6R)-4-((2S,4R,5S,6R)-4,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-5,10-dihydroxy-6-methyl-4-oxo-1,2,3,4-tetrahydroanthracen-2-yl)-2-methoxyacetamido)-3-(1H-indol-3-yl)propanamido)-3-(1H-indol-3-yl)propanoate

ID: ALA4166102

Chembl Id: CHEMBL4166102

PubChem CID: 145954961

Max Phase: Preclinical

Molecular Formula: C72H92N4O25

Molecular Weight: 1413.53

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](OC)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1

Standard InChI:  InChI=1S/C72H92N4O25/c1-30-48(97-53-24-49(61(80)32(3)93-53)98-52-23-47(77)60(79)31(2)92-52)22-37-18-36-19-42(67(90-8)70(87)75-45(20-38-28-73-43-16-12-10-14-40(38)43)69(86)76-46(71(88)91-9)21-39-29-74-44-17-13-11-15-41(39)44)66(65(84)58(36)64(83)57(37)59(30)78)101-55-26-50(62(81)34(5)95-55)99-54-25-51(63(82)33(4)94-54)100-56-27-72(7,89)68(85)35(6)96-56/h10-18,22,28-29,31-35,42,45-47,49-56,60-63,66-68,73-74,77-83,85,89H,19-21,23-27H2,1-9H3,(H,75,87)(H,76,86)/t31-,32-,33-,34-,35-,42-,45+,46+,47-,49-,50-,51-,52+,53+,54+,55+,56+,60-,61-,62-,63+,66+,67+,68-,72+/m1/s1

Standard InChI Key:  FJGXBRRHCWWBOW-YVDDUCCFSA-N

Alternative Forms

1. Parent:

   

   ALA4166102

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 1413.53

Molecular Weight (Monoisotopic): 1412.6051

AlogP: ┄

#Rotatable Bonds: ┄

Polar Surface Area: ┄

Molecular Species: ┄

HBA: ┄

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): ┄

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: ┄

CX LogP: ┄

CX LogD: ┄

Aromatic Rings: ┄

Heavy Atoms: ┄

QED Weighted: ┄

Np Likeness Score: ┄

References

1. Mitra P, Eckenrode JM, Mandal A, Jha AK, Salem SM, Leggas M, Rohr J..  (2018)  Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers.,  61  (17): [PMID:30114371] [10.1021/acs.jmedchem.8b01107]

Source

Source(1):

• Scientific Literature